These trials, characterized by their prospective nature and rigorous methodology, unveil compelling evidence of DPO's distinct advantages in anemia management, ranging from enhanced Hb elevation, reduced variability, and fewer dose adjustments to improved patient tolerability and simplified dosing regimens. The gene discussed is GSTM1; the disease is anemia (phenotype).